New drugs contribute to AbbVie’s upbeat 2020 view; shares hit year-high

AbbVie Inc on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc to drive growth beyond 2023, when its cash cow Humira loses patent protection.

…read more

Source:: Reuters – Business News